U.S. Supreme Court on Biologics Market Access

Now that the Supreme Court has issued its decision in the case of Sandoz v. Amgen, relating to certain aspects of the Biologics Price Competition and Innovation Act of 2009, IP Watchdog has posted a series of reactions to the ruling. The posting first summarizes the outcome of the case then provides insights from experts in the industry as to its implications. 

June 2017